Subscribe

TON - December 2022 Vol 15, No 6

Targeted Therapy with Brentuximab Vedotin Reduces Relapse Risk in Pediatric Patients with High-Risk Hodgkin Lymphoma
In the Literature, Lymphoma
TON - December 2022 Vol 15, No 6
Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS). Read More ›
Noteworthy Numbers: Ovarian Cancer
Noteworthy Numbers
TON - December 2022 Vol 15, No 6
Ovarian cancer is the fifth leading cause of cancer death among women in the United States. Read More ›
FDA News: October 21, 2021, and November 14, 2022
FDA Updates
TON - December 2022 Vol 15, No 6
This section provides a brief overview of new cancer drugs and new indications approved by the FDA between October 21, 2021, and November 14, 2022. Read More ›

Page 2 of 2

  • 1
  • 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.